Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 12:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Regorafenib Clear all
Terminated Phase 1 Interventional

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

NCT01187615
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Jun 27, 2026, 12:03 AM EDT
Completed No phase listed Observational

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

NCT05594147
View directory record Official record
Conditions
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
Interventions
Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506), Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

NCT03347292
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Withdrawn Phase 2 Interventional

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

NCT02287727
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer
Interventions
Laboratory Biomarker Analysis, Regorafenib
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
Buffalo, New York • Rocherster, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional

Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

NCT02116894
View directory record Official record
Conditions
Colorectal Cancer
Interventions
PF-03446962, Regorafenib
Biological · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Colorectal Cancer Patients

NCT02119676
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
Ruxolitinib, Regorafenib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
57
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT02278783
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
regorafenib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03465722
View directory record Official record
Conditions
GIST
Interventions
avapritinib, regorafenib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 2 Interventional Results available

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

NCT02383433
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Regorafenib, Gemcitabine Hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

NCT02098538
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Regorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

NCT01289821
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jun 27, 2026, 12:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

NCT04781192
View directory record Official record
Conditions
Advanced Biliary Tract Cancer
Interventions
Durvalumab, Regorafenib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Overland Park, Kansas • Westwood, Kansas • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional Results available

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

NCT03215264
View directory record Official record
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine, entinostat, regorafenib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 3 Interventional Results available

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

NCT01939223
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Laguna Hills, California • Los Angeles, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 1 Interventional

Regorafenib + Panitumumab for Colorectal Cancers

NCT02199223
View directory record Official record
Conditions
KRAS and NRAS Wild-type Colorectal Cancer
Interventions
regorafenib + panitumumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

NCT01002378
View directory record Official record
Conditions
Dietary Fats, Pharmacokinetics
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Jun 27, 2026, 12:03 AM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jun 27, 2026, 12:03 AM EDT
Suspended Phase 2 Interventional

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

NCT07071961
View directory record Official record
Conditions
Colorectal Cancer, Regorafenib, High Risk Patients
Interventions
Regorafenib (CT), Lorigerlimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 27, 2026, 12:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945
View directory record Official record
Conditions
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan, Panitumumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jun 27, 2026, 12:03 AM EDT
Active, not recruiting Phase 2 Interventional

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

NCT04803877
View directory record Official record
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
Interventions
Regorafenib 40 MG, Regorafenib 20MG, Nivolumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
5 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

NCT02795156
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
Interventions
Afatinib, Regorafenib, Cabozantinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jun 27, 2026, 12:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

NCT01322438
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (BAY73-4506) + rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jun 27, 2026, 12:03 AM EDT